Development and verification of the PAM50-based Prosigna breast cancer gene signature assay

BACKGROUND: The four intrinsic subtypes of breast cancer, defined by differential expression of 50 genes (PAM50), have been shown to be predictive of risk of recurrence and benefit of hormonal therapy and chemotherapy. Here we describe the development of Prosigna™, a PAM50-based subtype classifier a...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:BMC Med Genomics
Päätekijät: Wallden, Brett, Storhoff, James, Nielsen, Torsten, Dowidar, Naeem, Schaper, Carl, Ferree, Sean, Liu, Shuzhen, Leung, Samuel, Geiss, Gary, Snider, Jacqueline, Vickery, Tammi, Davies, Sherri R., Mardis, Elaine R., Gnant, Michael, Sestak, Ivana, Ellis, Matthew J., Perou, Charles M., Bernard, Philip S., Parker, Joel S.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2015
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4546262/
https://ncbi.nlm.nih.gov/pubmed/26297356
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12920-015-0129-6
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia